Targeting AR-driven enhancer condensates to overcome antiandrogen resistance in prostate cancer
Official title: Targeting m6A-eRNA and Mutant AR-Driven Enhancer Condensates to Overcome Antiandrogen Resistance in Prostate Cancer
Funded at University of Texas El Paso · NIH-11455463 · Data updated 2026-11-12
A patient-facing overview of a project that may help men with prostate cancer become more responsive to antiandrogen treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project start | September 17, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $649,097 |
| NIH project number | 1R01CA307343-01A1 |
| Project ID | NIH-11455463 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with prostate cancer whose disease may depend on androgen receptor signaling and may develop resistance to antiandrogen therapy.
✕Less likely to help
Patients whose cancer is not driven by androgen receptor signaling or who already respond perfectly to current therapies may see limited or no benefit.
What this research studies
This grant studies how changes in RNA and enhancer regions affect the androgen receptor in prostate cancer, with the goal of preventing or delaying resistance to common therapies. Researchers will look at how m6A RNA marks and AR-driven condensates influence cancer cell behavior and drug response. The work uses laboratory models to understand mechanisms that could lead to better therapies for people whose cancer stops responding to standard treatments.
Why it matters
Potential benefit: If successful, the findings could lead to new strategies to keep antiandrogen therapies effective for longer.
How similar studies have gone: Other studies in prostate cancer have shown that targeting AR signaling and RNA modifications can influence treatment response, though this exact approach is novel.
Where this research is happening
-
University of Texas El Paso
El Paso, United States Active
Researchers
- Principal investigator: Liu, Zhijie — University of Texas El Paso
- Study coordinator: Liu, Zhijie
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.